Dosing of medications in morbidly obese patients in the intensive care unit setting
- 3.2k Downloads
To derive recommendations for the dosing of commonly used medications in the morbidly obese patient in the ICU.
Articles were obtained through computerized searches involving MEDLINE. The bibliographies of retrieved publications and textbooks were reviewed for additional references.
All studies involving the pharmacokinetics or pharmacodynamics of medications in obese subjects or patients.
The emphasis was on studies involving morbidly obese patients but, in the absence of such data, investigations involving lesser forms of obesity were extracted.
There is a paucity of data upon which to make recommendations for dosing commonly used medications in the morbidly obese patient in the ICU, although recommendations were provided based on the available information.
There is clearly a need for more investigations involving dosing regimens of medications in the morbidly obese population. Until such studies are available, the clinician must try to derive the best dosing regimens for medications based on the limited pharmacokinetic data available for some agents and clinical judgement.
KeywordsMorbid obesity Dosing Pharmacokinetics Intensive care
- 4.Roubenoff R, Kehayias JJ (1991) The meaning and measurement of lean body mass. Nutrition Rev 49:163–175Google Scholar
- 5.Devine BJ (1974) Case number 25: gentamicin therapy. Drug Intell Clin Pharm 8:650–655Google Scholar
- 7.World Health Organization (1998) Obesity: preventing and managing the global epidemic, report of a WHO consultation on obesity. Geneva, June 3–5Google Scholar
- 8.National Heart, Lung and Blood Institute in cooperation with The National Institute of Diabetes and Digestive and Kidney Diseases (September 1998) Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults. NIH Publication No. 98–4083Google Scholar
- 11.Cheymol G (2000) Effects of obesity on pharmacokinetics. Clin Pharmacokinet 39:215–231Google Scholar
- 12.James WPT (1976) Research on obesity. Her Majesty’s Stationary Office, LondonGoogle Scholar
- 14.Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivias S (1993) The weight-based heparin dosing nomogram compared with a “standard care” nomogram. Ann Intern Med 119:874–881Google Scholar
- 21.Priglinger U, Karth GD, Geppert A, Joukhadour C, Berger R, Hulsman M, Pabinger I, Heinz G (2002) Prophylactic anticoagulation with low dose enoxaparin—is the subcutaneous route appropriate in the critically ill? Crit Care Med 29 (suppl):A97Google Scholar
- 35.Caldwell JB (1994) Intravenous ciprofloxacin dosing in a morbidly obese patient (letter). Ann Pharmacother 28:806Google Scholar
- 46.Davis RL, Quenzer RW, Bozigian HP, Warner CW (1990) Pharmacokinetics of ranitidine in morbidly obese women. DICP Ann Pharmacother 24:1040–1043Google Scholar
- 48.Bracken MB, Shepard MJ, Collins WF, Holford TR, Young W, Baskin DS, Eisenberg HM, Flamm E, Leo-Summers L, Maroon J, Marshall LF, Perot PL, Piepmeier J, Sonntag VKH, Wagner FC, Wilberger JE, Winn HR (1990) A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal cord injury. N Engl J Med 322:1405–1411PubMedGoogle Scholar
- 49.Bracken MB, Shepard MJ, Holford TR, Leo-Summers L, Aldrich EF, Fazl M, Fehlings M, Herr DL, Hitchon PW, Marshall LF, Nockels RP, Pascale V, Perot PL, Piepmeier J, Sonntag VKH, Wagner F, Wilberger JE, Winn HR, Young W (1997) Administration of methylprednisolone for 24 or 48 hours or tirilizad mesylate for 48 hours in the treatment of acute spinal cord injury. JAMA 277:1597–1604CrossRefPubMedGoogle Scholar
- 54.Gal P, Jusko WJ, Yurchak AM, Franklin BA (1978) Theophylline disposition in obesity. Clin Pharmacol Ther 23:438–444Google Scholar
- 61.Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Hoxter G, Mahagne MH, Hennerici M (1995) Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: The European Cooperative Acute Stroke Study (ECASS). JAMA 274:1017–1025PubMedGoogle Scholar